btg deal close mid-august conting
sale bsx bead busi surpris
divest embol bead conjunct btg deal close
agre sell portfolio drug-load microspher bland
malform hypervascular tumor varian mil
cover bead busi gener mil sale
includ oncozen embozen tandem drug-load microspher
embozen bland embol bead divestitur expect close
august immedi follow btg deal view surpris
close btg deal would involv sale bsx overlap
bead busi reiter outperform rate target
btg deal track close mid-august condit
divestitur identifi region regulatori review complet btg
expect close mid-august slightli later mgmt
origin expect mid-year btg share suspend august
end trade delist august
minor chang project due time divestitur
lower estim bsx bead busi reduc
inorgan sale contribut btg reflect later close date
august vs end june previous chang result reduct
ep minor impact organ growth
project stand
respect vs previous
valuat target price base ebitda multipl
ebitda bil risk product delay failur progress lrp
goal potenti new litig regulatory/qu issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
chang model
lower estim reflect sale compani bead busi
later expect btg deal close make minor adjust
year top-lin number bottom line ep estim come penni
beyond
figur chang model
compani mention price
